Thymic carcinoma: state of the art review

• Published in: International journal of radiation oncology, biology, physics Vol. 59; no. 3; p. 654
• Main Authors: Eng, Tony Y, Fuller, Clifton D, Jagirdar, Jaishree, Bains, Yadvindera, Thomas, Jr, Charles R
• Format: Journal Article
• Language: English
• Published: United States 01-07-2004
• Subjects: Humans; Neoplasm Staging - methods; Thymoma - diagnosis; Thymoma - pathology; Thymoma - therapy; Thymus Neoplasms - diagnosis; Thymus Neoplasms - pathology; Thymus Neoplasms - therapy
• ISSN: 0360-3016
• DOI: 10.1016/j.ijrobp.2003.11.021

Thymic carcinoma is a rare neoplasm with distinct clinical and pathological characteristics. The prognosis is often poor with an aggressive course that belies its numerical rarity. Potentially prognostic factors for survival include histopathologic grade, clinical stage, and resectability of the tumor. Five-year survival rates for all patients are approximately 30-50%, with a significant survival time differential between low-grade and high-grade neoplasms. Owing to the paucity of cases, optimal management of thymic carcinoma has yet to be defined. At present, a multimodality approach involving aggressive surgical resection, platinum-based combination chemotherapeutic interventions, and radiotherapy represent the preferred therapeutic approach. Though our knowledge remains somewhat speculative at present, several scientific, technological and therapeutic innovations may have a potentially significant impact on the future of this disease.